Brief: Atara Biotherapeutics And Pierre Fabre Laboratories Announce Publication Of Phase 3 Allele Tab-Cel® Data In The Lancet Oncology
31/01/2024 23:32
Jan 31 (Reuters) - Atara Biotherapeutics Inc ATRA.O :
* ATARA BIOTHERAPEUTICS AND PIERRE FABRE LABORATORIES
ANNOUNCE
PUBLICATION OF PHASE 3 ALLELE TAB-CEL® DATA IN THE LANCET
ONCOLOGY
* ATARA BIOTHERAPEUTICS INC - U.S. BLA ON TRACK FOR
SUBMISSION IN
Q2 2024 BASED ON STRONG CLINICAL FILE
* ATARA BIOTHERAPEUTICS INC: 51.2% OBJECTIVE RESPONSE RATE
AND
23.0 MONTH MEDIAN DURATION OF RESPONSE IN RELAPSED OR REFRACTORY
EBV+ PTLD PATIENTS
Source text for Eikon: ID:nBw7C1cTLa
Further company coverage: ATRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing